Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03875495 · OUTCOME

Tolerability and Safety of Temferon Over the First 90 Days Following Administration as Determined by the Incidence of CTCAEs

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) · Source last updated 2022-01-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
90 days

What was measured

0 participants analyzed. All the patients were withdrawn before treatment

Analysis population: Untreated patients

Groups in this outcome

Untreated Patients

3 Patients were recruited but did not receive Temferon

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Untreated Patients0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
0 participants analyzed. All the patients were withdrawn before treatment
groups
  1. description
    3 Patients were recruited but did not receive Temferon
    id
    OG000
    title
    Untreated Patients
population Description
Untreated patients
reporting Status
POSTED
time Frame
90 days
title
Tolerability and Safety of Temferon Over the First 90 Days Following Administration as Determined by the Incidence of CTCAEs
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice